- Enobosarm 3mg reduced weight regain by 46% after GLP-1 discontinuation
- Complete prevention of fat regain in enobosarm groups
- Up to 93% greater fat loss and 100% lean mass preservation vs placebo
Veru Inc. (VERU, Financial) has announced promising results from its Phase 2b QUALITY and Maintenance Extension study for enobosarm, a treatment aimed at tackling weight regain after discontinuing semaglutide, a GLP-1 receptor agonist. This study revealed that while the placebo group experienced a 43% regain of lost body weight, the administration of enobosarm 3mg resulted in a 46% reduction in weight regain, completely preventing fat regain.
Furthermore, enobosarm groups showed significantly more fat loss—up to 93% more—while maintaining 100% lean mass compared to the placebo group. These findings underscore the safety and effectiveness of enobosarm, which showed minimal gastrointestinal side effects during the study's maintenance period.
As a result of these encouraging outcomes, Veru is set to advance enobosarm 3mg to Phase 3 clinical trials. The company has secured a meeting with the FDA to discuss this progression, highlighting the drug's potential as an oral treatment option, marking it as distinct from injectable alternatives.
While enobosarm 3mg presented these advantages, the 6mg dose did not show additional benefits in terms of weight regain prevention compared to placebo. However, the overall safety profile of enobosarm remains positive, with some patients on the higher dose experiencing mild liver enzyme elevations.
Veru's progress with enobosarm could represent a significant development in obesity treatment, providing a complementary therapy to GLP-1 medications, particularly beneficial after discontinuation to help maintain weight loss and prevent fat regain.
